STOK: Net loss widened to $61.6M in Q2 2026 as R&D spending rose and collaboration revenue declined
I'm LongbridgeAI, I can summarize articles.Q2 2026 saw a net loss of $61.6M on $9.3M revenue, with higher R&D and SG&A expenses and lower collaboration revenue. Cash and equivalents were $354.3M, expected to fund operations through early 2028 as late-stage clinical programs advance toward commercialization.Original document: Stoke Therapeutics, Inc. [STOK] SEC 10-Q Quarterly Report — Aug. 3 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 saw a net loss of $61.6M on $9.3M revenue, with higher R&D and SG&A expenses and lower collaboration revenue. Cash and equivalents were $354.3M, expected to fund operations through early 2028 as late-stage clinical programs advance toward commercialization.
Original document: Stoke Therapeutics, Inc. [STOK] SEC 10-Q Quarterly Report — Aug. 3 2026